Highlights UroGen Pharma Ltd.

Equities

URGN

IL0011407140

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
14.04 ^USD	-0.78%		-2.30%	-6.40%

Apr. 15	UroGen Pharma Says FDA Accepts Investigational New Drug Application for Potential Bladder Cancer Treatment	MT
Apr. 03	UroGen Pharma Sues Teva Pharmaceuticals Over Alleged Patent Infringement of Jelmyto	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

UroGen Pharma Says FDA Accepts Investigational New Drug Application for Potential Bladder Cancer Treatment	Apr. 15	MT
UroGen Pharma Sues Teva Pharmaceuticals Over Alleged Patent Infringement of Jelmyto	Apr. 03	MT
UroGen Pharma Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
UroGen Pharma Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 14	CI
UroGen Pharma Ltd. Initiates Submission of a Rolling NDA to the FDA for UGN-102	Jan. 24	CI
Urogen Pharma Ltd. Enters into A License and Supply Agreement (The Agreement) with Medac Gesellschaft Für Klinische Spezialpräparate m.b.H	Jan. 17	CI
UroGen Pharma Ltd. Plans to Initiate Phase 3 Study in 2024	Jan. 17	CI
UroGen Signs Licensing Deal With Medac to Develop New Formulation for Urothelial Cancer; Shares Rise	Jan. 17	MT
UroGen Pharma Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Earnings Flash (URGN) UROGEN PHARMA Reports Q3 Revenue $20.9M, vs. Street Est of $20M	Nov. 14	MT
UroGen Pharma Ltd. Reiterates Revenue Guidance for the Full Year 2023	Nov. 14	CI
UroGen Pharma Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Earnings Flash (URGN) UROGEN PHARMA Posts Q2 Revenue $21.1M, vs. Street Est of $20.1M	23-08-10	MT
UroGen Pharma Ltd. Reiterates Earnings Guidance for the Full Year 2023	23-08-10	CI
UroGen Stock Up 49% on Full Enrollment for Bladder Cancer Study	23-07-27	DJ
UroGen Pharma Ltd. Announces Positive Topline Data From its Phase 3 Trials ATLAS and ENVISION studying UGN-102	23-07-27	CI
UroGen Pharma Ltd. Announces Retrospective Study Finds Jelmyto Use Effective Following Partial Ablation or Biopsy in Larger Volume Low-Grade Upper Tract Urothelial Tumors That Impede Kidney Preservation	23-07-10	CI
Urogen Pharma Ltd. Announces the Results of Sub-Analysis from the First Post- Commercial Utilization Review of JelmytoÂ®? Forpyelocalyceal Solution	23-06-20	CI
UroGen Pharma Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Earnings Flash (URGN) UROGEN PHARMA Posts Q1 Revenue $17.2M, vs. Street Est of $17.1M	23-05-11	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights UroGen Pharma Ltd.

Equities

URGN

IL0011407140

Highlights

Filters